A recent report published by Infinium Global Research on paroxysmal nocturnal hemoglobinuria treatment (PNH) market provides an in-depth analysis of segments and sub-segments in the global as well as regional paroxysmal nocturnal hemoglobinuria treatment market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional paroxysmal nocturnal hemoglobinuria treatment market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global paroxysmal nocturnal hemoglobinuria treatment market. According to the report, the global paroxysmal nocturnal hemoglobinuria treatment market is projected to grow at a CAGR of 11.6% over the forecast period of 2019-2025.
Paroxysmal nocturnal hemoglobinuria is a rare acquired, life-threatening disease of the blood. The disease is characterized by the destruction of red blood cells (hemolytic anemia), blood clots (thrombosis), and impaired bone marrow function (State where blood components do not form in adequate proportion). PNH affects 0.5-1.5 persons per million of the population and is mainly a disease of younger adults. PNH occurs when mutations of a gene called PIG-A occur in a bone marrow stem cell. The function of Stem cells includes the production of mature blood elements like red blood cells, white blood cells, and platelets. Thus the mutated stem cells pass the PIG-A mutation to all cells derived from an abnormal stem cell. Cells carrying PIG-A mutations are deficient with GPI-anchored proteins, which play an important role in the protection of RBCs from destruction, blood clotting and involved in fighting against infection. The survival rate in younger adults after diagnosis is 10 years, however, some patients can survive for decades with only minor symptoms.
The high growth of paroxysmal nocturnal hemoglobinuria treatment market will attribute by factors such as the rising number of blood and bone marrow related disorders. National Organization for Rare Diseases (NORD) report states around 0.5-1.5 per million general population suffer from PNH. Other factors will contribute to the market growth is development in stem cell research, advancement in stem cell transplantation therapies and heavy investments for novel drug discovery (NDD). APL-2, a Complement C3 Inhibitor by Apellis pharmaceuticals is under clinical trial phase 3 for the potential treatment of paroxysmal nocturnal hemoglobinuria. However high costs associated with medical treatment and adverse side effects with existing treatments can hamper the growth of the market. On the other hand, unmet demand for drugs in developing countries can provide better growth opportunities to paroxysmal nocturnal hemoglobinuria treatment market.
Based on geography North America, specifically, the US will hold the highest share of the market in the near future, factors such as approval for novel drugs in the pipeline, adoption of novel therapeutics will support the growth of the region in the forecast period. The market in Europe is anticipated to grow with a healthy rate in the near future, pharma major collaboration with research institutes for new drug development and high expenditure on the healthcare sector will contribute to the growth of the market. The Asia-Pacific region is expected to be on the second spot in the paroxysmal nocturnal hemoglobinuria treatment market in the forecast period. An increase in healthcare expenditure, the presence of key pharma players, and rising healthcare awareness is contributing to the growth of this region.
The report on global paroxysmal nocturnal hemoglobinuria treatment market covers segments such as diagnostic test and treatment. On the basis of diagnostic test, the sub-markets include complete blood count test (CBC), lactate dehydrogenase test (LDH), bone marrow examination, urine test for hemosiderin, flow cytometry, and other tests. On the basis of treatment, the sub-markets include medication, stem cell transplant, and blood transfusion.
The report provides profiles of the companies in the market such as F. Hoffmann-La Roche AG, Akari Therapeutics, Alexion Pharmaceuticals, lnc., Ra Pharmaceuticals, Novartis AG, Alnylam Pharmaceuticals, Inc., Apellis Pharmaceuticals, Achillion Pharmaceuticals, Regeneron Pharmaceuticals, Inc., and Other Companies.
The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of paroxysmal nocturnal hemoglobinuria treatment market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.
Get free analyst support for the queries before and post purchasing report.
Be assured of 100% customer satisfaction about the research and get 24X7 customer support.
Infinium has achieved over 400%+ growth in its repository and revenue over the last 2 years. Yes, we are proud to say we are growing at a great pace and becoming a trusted partner among our clients.
sign up for our newsletter